WASHINGTON, DC--(Marketwire - June 10, 2010) -
| Highlighted Links |
|
|
DIA 2010 Booth #221 -- INC Research ®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, will unveil the details of its QualityFinish® Camp, a new component featured in the last phase of its Trusted Process® at the 46th Annual DIA Meeting in Washington, DC, June 14-17 at booth #221.
Adopting proven project management techniques used in QuickStart® Camp at the beginning of a study, the entire team dedicates time to focus on the completion of project close-out activities and review of draft statistical data deliverables during the QualityFinish Camp. It is designed to reinforce the commitment and project ownership built in the phases that precede it.
The key benefits of the Camp are the reduction of cycle time and rework for close-out activities and documents. In fact, when comparing against historical data prior to the formalized QualityFinish phase, database lock occurs 54 percent faster because of higher quality data and a strong sense of project ownership.
“When the focus of a clinical trial shifts from patients to data during QualityFinish, we want the entire team to collaborate on project deliverables to keep the trial on time and on budget,” said John Potthoff, chief operating officer, INC Research. “Because these meetings are professionally facilitated with clear objectives, we have already received positive feedback from our customers who gain even more confidence towards the end of a trial.”
The topic of study completion and initiation will also be discussed by Alistair Macdonald, executive vice president, Strategic Development, during the session on “Clinical Trials: The Race to Study Launch and Speed to Finish” on June 14 at 3:30 p.m.
Nick Lucas, PhD, VP, Global Data Management, will share his views on “Electronic Health Records (EHR) and Data Management: What it Means for Us in Clinical Data Management” on June 15 at 10:00 a.m.
Nina Piskareva, MD, executive director, Drug Safety and Pharmacovigilance, will discuss why sponsors need to know when, how and who is required to submit blinded and unblinded SUSARs in her presentation on “Clarifying Blinded and Unblinded Suspected Unexpected Serious Adverse Reaction (SUSAR) Reporting in the US and Europe” on June 16 at 10:30 a.m.
About INC Research® Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.
Contact:
Kelly Foster
+1 619-224-1261
Email Contact
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
